We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.

Current dialysis vascular access patient education materials can be overwhelming, not written in plain language, and not have enough realistic information about the steps involved in getting a dialysis vascular access before starting hemodialysis. This study is being done to create and test a dialysis vascular access educational video for patients. Participants would take part in a one-time interview about their thoughts on dialysis vascular access education and their ideas for a vascular access video.

The research aims to improve how we check for Hepatitis C Virus (HCV) in different healthcare settings, making it easier for people to get tested. We want to see how accurately this test can detect HCV infection in people who might have symptoms or are at risk. We are using a type of blood sample called "EDTA capillary whole blood," which is a small amount of blood collected in a tiny tube with a special substance to prevent it from clotting. This study helps us understand if the Xpert HCV test can be reliable in practical situations where anyone can use it. The goal is to make sure this test is good at finding Hepatitis C infections, especially in places where not many healthcare professionals are available.

The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

We are surveying individuals with sickle cell disease (SCD) and/or parents of a child with SCD to get a sense of the types of treatment they would choose based on the harms and benefits of those treatment options. The proposed study will be designed to meet the following objectives: 1) Elicit individual respondent's maximum acceptable risk (MAR) for treatment benefits 2) Elicit individual respondent's minimum 3) Characterize heterogeneity in MARs and MABs among respondents

A multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with stent omission versus placement of a ureteral stent.

This study will collect information about children who have rare types of lung disease to help us understand how better to diagnose and treat these patients. Information will be collected from participants' doctors about how different aspects of their disease and treatment. This will be compared to information from other such patients from other hospitals around the United States. By gathering information on many such patients, we hope to develop best practices for such patients. These may lead to new research studies, which we can invite participants in this study to consider as well.

The mission of the Collaborative Islet Transplant Registry (CITR) is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America, Europe and Australia.

The rationale for this study is to determine if there is a difference in symptoms or complications among patients undergoing uncomplicated ureteroscopy for stone removal with shorter indwelling stent duration. Curently there are only a few small studies exploring the optimal duration of stent placement after stent placement and no multicenter randomized control trials.

To test the effect of automated RBC exchange transfusion and standard of care compared with standard of care on the number of episodes of clinical worsening of sickle cell disease (SCD)requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 12 months in high risk adult SCD patients.